New hope for hard-to-treat brain cancer: combo therapy enters phase 2 trial
NCT ID NCT06931652
First seen Feb 15, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or not responded to prior treatment. About 60 adults will take part to see if the combination can shrink tumors and how safe it is. The goal is to control the disease, not cure it, as ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CNS LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie
ACTIVE_NOT_RECRUITINGMarseille, France
-
CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie
ACTIVE_NOT_RECRUITINGNancy, France
-
CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire
ACTIVE_NOT_RECRUITINGTours, France
-
CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang
RECRUITINGLille, France
Contact
-
CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique
RECRUITINGClermont-Ferrand, France
Contact
-
CHU LYON-SUD - Hématologie Clinique
RECRUITINGPierre-Bénite, France
Contact
-
CHU PONTCHAILLOU - Hématologie Clinique
NOT_YET_RECRUITINGRennes, France
Contact
-
GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie
ACTIVE_NOT_RECRUITINGParis, France
-
HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique
ACTIVE_NOT_RECRUITINGParis, France
-
INSTITUT BERGONIE - Service d'Oncologie Médicale
ACTIVE_NOT_RECRUITINGBordeaux, France
-
INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie
ACTIVE_NOT_RECRUITINGSaint-Cloud, France
-
INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie
RECRUITINGCaen, France
Contact
-
IUCT ONCOPOLE - Service Hématologie
RECRUITINGToulouse, France
Contact
Conditions
Explore the condition pages connected to this study.